references
- Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000;39:233–42.
- van den Heuvel M, van Bragt A, Alnabawy A, et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: The vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005;72:168–74.
- Novák A, de la Loge C, Abetz L, et al. The combined contraceptive vaginal ring, NuvaRing: An international study of user acceptability. Contraception 2003;67:187–94.
- Roumen FJ. Review of the combined contraceptive vaginal ring, NuvaRing. Ther Clin Risk Manag 2008;4:441–51.
- Shimoni N, Westhoff C. Review of the vaginal contraceptive ring (NuvaRing®). J Fam Plann Reprod Health Care 2008;34:247–50.
- Mulders TM, Dieben TO. Use of the novel combined contraceptive vaginal ring for ovulation inhibition. Fertil Steril 2001;75:865–70.
- Oddsson K, Leifels-Fischer B, Wiel-Masson D, et al. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 μg ethinylestradiol and 150 μg levonorgestrel: A randomized trial. Hum Reprod 2005;20:557–62.
- Milsom I, Lete I, Bjertnaes A, et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 μg ethinyl estradiol and 3 mg drospirenone. Hum Reprod 2006;21:2304–11.
- Bjarnadóttir RI, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol 2002;186:389–95.
- Schering-Plough News Release. Schering-Plough announces imperfect contraceptive use impacts women's emotional well-being. 2008. Accessed 28 August 2010 from: http://www.merck.com/newsroom/news-release-archive/schering-plough-news-arch ive/all/releaseid=1130685.html
- Roumen FJ, op ten Berg MM, Hoomans EH. The combined contraceptive vaginal ring (NuvaRing): First experience in daily clinical practice in The Netherlands. Eur J Contracept Reprod Health Care 2006;11:14–22.
- Merki-Feld GS, Hund M. Clinical experience with NuvaRing in daily practice in Switzerland: Cycle control and acceptability among women of all reproductive ages. Eur J Contracept Reprod Health Care 2007;12:240–7.
- Brucker C, Karck U, Merkle E. Cycle control, tolerability, efficacy and acceptability of the vaginal contraceptive ring, NuvaRing: Results of clinical experience in Germany. Eur J Contracept Reprod Health Care 2008;13:31–8.
- Yonkers KA, O'Brien PM, Eriksson E. Premenstrual syndrome. Lancet 2008;371:1200–10.
- Gallo MF, Nanda K, Grimes DA, et al. 20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev 2008;8:CD003989.
- Ornstein RM, Fisher MM. Hormonal contraception in adolescents: Special considerations. Paediatr Drugs 2006;8:25–45.
- Clayton AH. Symptoms related to the menstrual cycle: Diagnosis, prevalence, and treatment. J Psychiatr Pract 2008;14:13–21.
- The ESHRE Capri Workshop Group. Noncontraceptive health benefits of combined oral contraception. Hum Reprod Update 2005;11:513–25.
- Usman SB, Indusekhar R, O'Brien S. Hormonal management of premenstrual syndrome. Best Pract Res Clin Obstet Gynaecol 2008;22:251–60.
- Allais G, Castagnoli Gabellari I, De Lorenzo C, et al. Menstrual migraine: Clinical and therapeutical aspects. Expert Rev Neurother 2007;7:1105–20.